<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961270</url>
  </required_header>
  <id_info>
    <org_study_id>CAMS-ZH-001</org_study_id>
    <nct_id>NCT02961270</nct_id>
  </id_info>
  <brief_title>Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation</brief_title>
  <official_title>Clinical Activity of Icotinib in Patients With Advanced Non-small-cell Lung Cancer Harbouring Uncommon EGFR Mutations: a Single-arm, Prospective, Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in
      non-small cell lung cancer patients harboring uncommon EGFR mutation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor response rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity</description>
    <arm_group_label>icotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stage IIIB/IV non-small cell lung cancer

          -  Patients with uncommon epidermal growth factor receptor (EGFR) mutation

          -  Targeted-therapy-naive patients

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

          -  Evaluable target lesions according to RECIST 1.1 for tumour response assessment

        Exclusion Criteria:

          -  Wild-type EGFR

          -  Positive 19 del and/or 21 L858R mutation

          -  Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib

          -  Patients who have documented history of interstitial lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengyu Zhou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenyu Zhou, MD</last_name>
    <phone>86 13520852899</phone>
    <email>typhoonwho@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengyu Zhou, MD</last_name>
      <email>typhoonwho@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>November 10, 2016</last_update_submitted>
  <last_update_submitted_qc>November 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shengyu Zhou</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

